ArticlePublic health genomics2013
Who gets genomic testing for breast cancer recurrence risk?
Article in Public health genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Experiences accessing and receiving tumour genetic profiling in Victoria: a consumer-led cross-sectional survey study.BMC cancer · 2026Article
- Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.BMC cancer · 2020Article
- Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling.Translational oncology · 2020Article
- Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.Ontario health technology assessment series · 2020Article
- Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.Breast cancer research and treatment · 2019Article
- Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.American journal of respiratory and critical care medicine · 2018Article
- Operationalizing the Reciprocal Engagement Model of Genetic Counseling Practice: a Framework for the Scalable Delivery of Genomic Counseling and Testing.Journal of genetic counseling · 2018Article
- Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Low utility of Oncotype DX® in the clinic.Cancer medicine · 2017Article
- Implementation of the 21-gene recurrence score test in the United States in 2011.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Article
- Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.International journal of technology assessment in health care · 2016Article
- Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Article
- Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Clinical breast cancer · 2015Observational
- Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.World journal of surgical oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND/
aimsOur study examined whether patient characteristics, beliefs and decision-making styles were associated with uptake of genomic testing for breast cancer recurrence risk.
methodsParticipants were 132 early-stage breast cancer patients eligible for the Oncotype DX genomic test. We interviewed patients in 2009-2010 and obtained information from medical charts.
resultsHalf of the women eligible for genomic testing for breast cancer recurrence risk received it. The most common reason for not getting the test was that women's physicians did not offer it (80%). Test recipients were more likely to be unsure about receiving chemotherapy treatment compared to women who did not receive the test (p < 0.05). Women who received the test had less advanced disease pathologies, recalled a lower objective recurrence risk, perceived lower recurrence risk, and were slightly younger (all p < 0.05). Most women who described their decision-making style as active received the test (75%), whereas few women who described their style as passive received the test (12%) (p < 0.01).
conclusionIn the university clinic we studied, genomic testing appeared to be more common among patients who may benefit most from the information provided by results, but confirmation in larger studies is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.